Switching From Wegovy Injections to Foundayo

Wegovy (semaglutide) injections are an effective weight loss aid clinically proven to help fight obesity when used alongside a healthy diet and regular exercise. However, some people may feel apprehensive about the injection process and prefer an alternative administration method.

Foundayo (orforglipron) offers one such option. Instead of a weekly injection like Wegovy, it is taken as a daily pill that can be administered at any time of day. This makes it different to the Wegovy Pill, which has to be taken according to a strict regimen.

We’ve already compared Wegovy injections and Foundayo in another article, so this time we’ll walk you through the process of switching medications if you’re considering swapping semaglutide for orforglipron to continue your weight loss journey.

Our guide to switching from Wegovy injections to Foundayo covers everything you need to know so you can make a more informed decision about what approach best fits your circumstances.  

START YOUR CONSULTATION TODAY

Is it Possible to Switch From Wegovy Injections to Foundayo?

It’s possible to switch from Wegovy injections to Foundayo, and there are many reasons to consider the change. However, you should think carefully about what you hope to accomplish by changing from one GLP-1 medication to another. It’s also important to discuss these weight loss and health goals with a licensed clinician to confirm that Foundayo is the right choice for you.

Changing your treatment plan requires close clinical supervision, as different GLP-1 medications vary in strength and use. This means you can’t simply swap your Wegovy injection for a comparable  Foundayo pill; only a healthcare professional can formulate an appropriate dosing schedule and advise you on how to safely adjust your treatment plan.

Who is Eligible to Switch?

You can switch from Wegovy to Foundayo if your prescriber agrees the change is medically appropriate and you meet Foundayo’s prescription criteria. To make this decision, a clinician will assess your medical history, current treatment, and reasons for switching.

​To be prescribed Foundayo, UK patients must have a BMI of 30 kg/m2 or a BMI between 27 kg/m2 and 30 kg/m2 with at least one weight-related health problem. Examples of weight-related medical conditions include:

• Prediabetes (i.e., high blood sugar)
• Type 2 diabetes
• Hypertension (high blood pressure)
• High cholesterol
• High triglyceride levels
• Cardiovascular disease

​You can’t take Foundayo if you have an allergy to orforglipron or any other of the medication’s ingredients. It is also not recommended for people with severe liver impairment or congestive heart failure.

Researchers don’t yet know how orforglipron may affect pregnant or breastfeeding women. Therefore, you shouldn’t take Foundayo if you are pregnant, planning to become pregnant, or breastfeeding. Doctors advise women of childbearing potential to use reliable contraception throughout Foundayo treatment.

It’s important to note that orforglipron (the active ingredient in Foundayo) can make oral hormonal contraceptives less effective. Doctors advise women to add a second non-oral or barrier form of contraception (such as condoms or the coil) for 30 days after starting treatment, and 30 days following each dose increase. If you’re planning a pregnancy, you should also stop taking Foundayo for at least three weeks before attempting to conceive.

Why Consider Changing From Wegovy Injections to Foundayo

There are many potential reasons to consider changing from Wegovy injections to Foundayo. These may include a preference for pills over injections, or a desire to maintain weight loss achieved on Wegovy. Some people may struggle to manage Wegovy's gastrointestinal side effects and hope a different GLP-1 medication will cause milder side effects.

1. Choosing Tablets Over Injections

A key reason for switching from Wegovy to Foundayo is the method of administration. Wegovy, like most GLP-1 therapies available in the UK, is a self-administered injectable medication. Learning to inject Wegovy is a simple process, but fear of needles, a tendency for injection site reactions, and mobility issues can all make self-injection challenging.

Wegovy injection pens also require refrigeration before their first use and must be fitted with a new needle before each use. This can be inconvenient for people with busy schedules or frequent travellers, compared to taking a daily pill. Therefore, swapping Wegovy injections for Foundayo pills can make it easier to adhere to your treatment schedule by eliminating injection-related challenges.

2. Maintaining Weight Loss

It’s common for people who have been using Wegovy for a long time to reach a weight loss plateau. If you are satisfied with how much weight you have lost, switching to Foundayo can help you maintain your lower weight after discontinuing Wegovy injections.

Weight gain after stopping weight loss injections is common, with one study finding that people regained two-thirds of their prior weight loss in the year after discontinuing Wegovy. Further research suggests Foundayo could help prevent this. One clinical trial found that people who started taking Foundayo after stopping Wegovy maintained 79.3% of their weight loss, compared to just 37.6% among those on a placebo.

3. Managing Side Effects

Gastrointestinal issues are common side effects of all GLP-1 medications, with the most common being nausea, vomiting, diarrhoea, and constipation. These symptoms are generally mild-to-moderate in severity and improve over time, though individual responses can vary. Side effects that are difficult to manage can negatively impact quality of life and may even lead some people to discontinue treatment.

​If you experience persistent side effects on Wegovy, taking a different GLP-1 may mitigate your symptoms. However, switching from Wegovy to Foundayo does not guarantee fewer side effects, as both drugs work similarly in the digestive system. If you are struggling to manage gastrointestinal symptoms on Wegovy, discuss your concerns with a prescribing clinician for individual advice.

What Dose of Foundayo Will You Start With?

Because both medications contain different active ingredients, switching from Wegovy injections to Foundayo is not as simple as moving from one dose to another. Instead, you will most likely start on a lower dose of orforglipron and work your way through the dosage schedule. This allows your body to adjust to the new medication and reduces the risk of side effects.

Where you start with Foundayo will depend on several factors, including your current Wegovy dose, how your weight loss is progressing, and whether you are tolerating side effects. The table below outlines what your first dose of orforglipron could be with Prescription Doctor, though this is not a guarantee. 
 

Deciding where to start with Foundayo is on a case-by-case basis. Our experienced clinicians will review your individual circumstances and determine the most appropriate dose for you.

Instead of administering one injection per week, your new routine will have you take a Foundayo tablet every day. Consistency matters, so try to tie the pill to a regular task, like taking it with a glass of water in the morning.  

How Do the Side Effects Compare?

Like other GLP-1 medications, Wegovy and Foundayo frequently cause gastrointestinal side effects such as nausea, vomiting, diarrhoea, and constipation. Other potential side effects of Wegovy and adverse reactions to Foundayo include:

• Headaches
• Stomach pain
• Feeling weak or tired
• Dizziness
• Indigestion
• Burping and gas
• Bloating
• Heartburn
• Gallstones
• Hair loss
• Injection site reactions (Wegovy injections only)
• Skin sensitivity
• Rapid heart rate
• Low blood pressure
• Hypoglycemia (very low blood sugar)

​The side effect profiles of Wegovy and Foundayo are very similar because they belong to the same drug class. Both mimic the naturally occurring gut hormone, GLP-1, and activate the same biological pathways in the body. 

​Foundayo and Wegovy can also increase your risk of acute pancreatitis, an urgent medical condition in which the pancreas becomes inflamed. Vomiting and diarrhoea caused by GLP-1 medications can lead to dehydration, which, if severe, can result in kidney damage. If you experience severe or persistent side effects during your GLP-1 treatment, seek medical attention right away.

How to Switch From Wegovy Injections to Foundayo

If you want to switch from Wegovy to Foundayo, first discuss your reasons for the change with a licensed clinician. If they agree Foundayo is right for you, they will create a new treatment plan based on your medical history and weight-loss goals.

​You should not take Wegovy and Foundayo together, and always follow a clinician-approved dosing schedule when switching between GLP-1 therapies. Taking both treatments at the same time may increase your risk of severe gastrointestinal side effects.

​Your prescriber will likely recommend starting Foundayo one week after your last Wegovy injection. No official dose-conversion guide exists for Wegovy and Foundayo, so your clinician will recommend a starting dose based on your individual needs and treatment history. Once you start Foundayo, you can follow the Foundayo dosing regimen to increase the medication's effects as needed.

Will Changing from Wegovy Injections to Foundayo Affect Progress?

Switching from Wegovy to Foundayo can affect your progress, depending on where you are in your weight loss journey. Wegovy and Foundayo are both effective weight reduction therapies, but Wegovy may produce more significant results than Foundayo. One large clinical trial reported an average body weight reduction of 14.9% among participants on 2.4 mg Wegovy after 68 weeks of treatment. A similar study of orforglipron found an average weight loss of 12.4% of total body weight after 72 weeks on the highest Foundayo dose. So if you’re still trying to actively lose weight, your progress may slow down on Foundayo.

However, some people use Foundayo to maintain weight loss, rather than increase it. People who meet their weight loss goals on Wegovy may feel ready to stop the injections, but have concerns about the potential effect on their waistline. When you stop taking a GLP-1, appetite returns, and studies estimate that people regain, on average, 60% of their lost weight within a year of stopping Wegovy.

Switching to Foundayo may reduce this risk and make it easier to maintain weight loss after coming off Wegovy. If you’ve reached a plateau on Wegovy, Foundayo may not restart weight loss, but it could help you to maintain a lower weight.

Foundayo (Orforglipron)

Rated 0 out of 5 based on 0 reviews

Rated 0 out of 5 based on 0 reviews

• Oral GLP-1 tablet
• Manufactured by Eli Lilly
• Clinical trials show weight loss of around 12.4% after 72 weeks

• Discreet delivery next working day
• Online prescription - No doctor visit

Prices from £109.00 Review More Prices

Start Order More Info

Get Started

Start Order More info

What to Expect After Making the Switch

When switching from Wegovy injections to Foundayo, your prescribing clinician will recommend a dosing schedule that allows you to transition safely from one medication to the other. This may include a brief pause between medications (sometimes called a washout phase) before you start taking Foundayo.

First 3 Months

The first three months of Foundayo treatment will likely focus on starting and titrating the medication. The official starting dose for Foundayo is 0.8 mg per day for at least 30 days. You can escalate your dose to 2.5 mg in month two, and to 5.5 mg by month three. These gradual increases give your body time to adjust to the medication and may help reduce gastrointestinal side effects.

You should only increase your Foundayo dose if the treatment is working for you and the side effects are manageable. If you have unmanageable or severe gastrointestinal symptoms, contact your prescribing clinician to discuss pausing treatment or reducing your Foundayo dose.

First 6 Months

By month 6 of Foundayo treatment, people who increase their dose at 30-day intervals will have reached the maximum dose of 17.2 mg daily. You may now lose weight at a steady rate, as the medication's appetite-suppressing effects reduce food cravings and calorie intake. However, your rate of weight loss may be slower than it was on Wegovy.

If you are using Foundayo for weight maintenance, your weight may remain relatively stable. In one clinical trial, participants who switched from Wegovy to Foundayo maintained 79.3% of their weight loss.

Can You Change Back from Foundayo to Wegovy Injections?

You can change back from Foundayo to Wegovy injections, and may wish to do so if you’re dissatisfied with your weight loss progress or experience unmanageable side effects. As before, discuss your intentions with a licensed clinician before changing your treatment plan.

You may need to start on a lower Wegovy dose and titrate up again, rather than going straight back to your previous Wegovy dose. You may also need to pause medications briefly. A healthcare professional will create a safe dosing schedule to support the best possible treatment outcome.

Support Throughout Your Entire Journey

If you’re considering switching from Wegovy injections to Foundayo, or thinking about any other aspect of your weight loss journey, the good news is that you don’t have to make any important decisions alone. Prescription Doctor is here to help. Since 2013, we’ve supported countless individuals in reaching their goals, and we’re perfectly placed to do the same for you.

Our experienced clinicians are always on hand to discuss what’s best for your circumstances and are committed to offering a truly personalised service. It’s no surprise, therefore, that we’ve built a strong reputation for quality. Get in touch today to learn more or start an online weight loss consultation. 

Authored & Reviewed By

Kate Latham

Medical Content Writer

Kate has been a scientific content writer since 2017. With a BSc in Biology and a background in cancer research, she is adept at identifying the latest findings in medical research and utilising these

Published on: 21/10/2026 Reviewed on: 21/10/2026